0
Commentary |

N- methyl-D-aspartate Glutamate Receptor Antagonists and the Promise of Rapid-Acting Antidepressants

John H. Krystal, MD
Arch Gen Psychiatry. 2010;67(11):1110-1111. doi:10.1001/archgenpsychiatry.2010.138.
Text Size: A A A
Published online

Extract

The exciting findings reported by Diazgranados and her collagues1 regarding the antidepressant efficacy of the uncompetitive N- methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine in depressed patients with bipolar disorder add to the emerging interest in rapid-acting antidepressants (RAAs).

Their article describes robust, clinically relevant, and rapid alleviation of depression symptoms in patients with bipolar disorder that persists far beyond the presence of the drug in the body. Ketamine has a terminal half-life of approximately 3 hours. Yet after 2 days, or 16 half-lives, of ketamine, the effect size of its antidepressant effects was large (0.8). Impressively, at 2 weeks there were still traces of the antidepressant effects of single ketamine dose, associated with an effect size of 0.22. Further, 6 of 17 patients had a clinical response to ketamine within 40 minutes of infusion and 9 of 16 patients experienced a remission of their depression during the study. The magnitude of these ketamine effects was particularly impressive because the changes were observed in patients who had treatment-resistant symptoms and who were already receiving mood-stabilizing medications. These data suggest that the benefits of ketamine in patients with bipolar disorder mirror those reported earlier for patients with unipolar depression.24

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();